Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BilaDex-P is a fixed-dose combination syrup containing the second-generation antihistamine bilastine, the cough suppressant dextromethorphan, and the nasal decongestant phenylephrine. Developed by Ind Blues Pharma, it is indicated for the symptomatic relief of the common cold, hay fever, and upper respiratory allergies, particularly in pediatric patients. Bilastine acts as a selective peripheral H1 receptor antagonist to alleviate allergic symptoms like sneezing and runny nose without causing significant drowsiness. Dextromethorphan is a centrally acting antitussive that suppresses the cough reflex in the brain to relieve dry, irritating coughs. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal passages, reducing swelling and congestion to improve breathing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bilastine + dextromethorphan + phenylephrine.